Compare MDAI & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDAI | EVAX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | Denmark |
| Employees | 78 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 31.9M |
| IPO Year | N/A | 2020 |
| Metric | MDAI | EVAX |
|---|---|---|
| Price | $1.44 | $3.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.25 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 731.6K | 32.4K |
| Earning Date | 05-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $63.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $1.20 |
| 52 Week High | $3.21 | $12.15 |
| Indicator | MDAI | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 55.22 |
| Support Level | $1.25 | $2.45 |
| Resistance Level | $1.48 | $4.64 |
| Average True Range (ATR) | 0.15 | 0.36 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 42.58 | 44.32 |
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.